新浪登录
腾讯登录Am J Pathol：ALDH1基因的表达水平与非小细胞肺癌（NSCLC）患者的预后有关
| 导读 | <a href="http://img.360zhyx.com/uploads/2012/10/未命名21.jpg"><img class="aligncenter size-full wp-image-5179" title="未命名2" src="http://img.360zhyx.com/uploads... |
<a href="http://img.360zhyx.com/uploads/2012/10/未命名21.jpg"><img class="aligncenter size-full wp-image-5179" title="未命名2" src="http://img.360zhyx.com/uploads/2012/10/未命名21.jpg" alt="" width="158" height="204" /></a>
众多研究已证实ALDH1（乙醛脱氢酶1）是多种癌症干细胞的替代标记物，如：乳癌组织如果出现ALDH1表达就意味着以后不良。通过定量测定两组NSCLC病人体内的ALDH1表达，研究人员明确了ALDH1的预后意义：与乳癌不同，非小细胞肺癌如果出现ALDH1表达，那么预后更好.
<!--more-->
<br/><strong>原文摘要：</strong><br/>
<em><br/><strong>Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer</strong><br/>
</em>
Aldehyde dehydrogenase 1 (ALDH1) has been suggested as a surrogate biomarker for cancer stem cells in breast cancer and other tumors. We quantitatively measured ALDH1 in two large cohorts of patients with non-small cell lung cancer (NSCLC) and investigated its prognostic value. The AQUA method of quantitative immunofluorescence was used to measure ALDH1 in 134 patients with NSCLC from Yale University and 296 patients with NSCLC from Sotiria and Patras University hospitals in Greece, using tissue microarrays. Patients were classified as positive or negative for ALDH1 based on the detection threshold for quantitative immunofluorescence. Patients with squamous cell carcinoma had higher scores than patients with adenocarcinoma. Detectable ALDH1 predicted better prognosis in both cohorts (<em>P</em> = 0.0035 for the Yale cohort; <em>P</em> = 0.0238 for the Sotiria/Patras cohorts). The effect of ALDH1 expression was independent of clinicopathologic factors in the Yale cohort (risk ratio = 3.2, <em>P</em> = 0.0008), but did not reach significance in the Sotiria/Patras cohort (hazard ratio = 1.51, <em>P</em> = 0.08). Among patients with adenocarcinoma, the ALDH1-negative group had shorter survival compared with the ALDH1-positive group in the Yale cohort (<em>P</em> = 0.00001), but not in the Sotiria/Patras cohort (<em>P</em> = 0.45). Unlike breast cancer, in which ALDH1 expression predicts poor outcome, in NSCLC our exploratory and retrospective study indicates that ALDH1 expression is associated with favorable outcome.
<br/>来源：医学专业新闻
链接：http://www.journals.elsevierhealth.com/periodicals/ajpa/article/S0002-9440(12)00519-6/images
众多研究已证实ALDH1（乙醛脱氢酶1）是多种癌症干细胞的替代标记物，如：乳癌组织如果出现ALDH1表达就意味着以后不良。通过定量测定两组NSCLC病人体内的ALDH1表达，研究人员明确了ALDH1的预后意义：与乳癌不同，非小细胞肺癌如果出现ALDH1表达，那么预后更好.
<!--more-->
<br/><strong>原文摘要：</strong><br/>
<em><br/><strong>Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer</strong><br/>
</em>
Aldehyde dehydrogenase 1 (ALDH1) has been suggested as a surrogate biomarker for cancer stem cells in breast cancer and other tumors. We quantitatively measured ALDH1 in two large cohorts of patients with non-small cell lung cancer (NSCLC) and investigated its prognostic value. The AQUA method of quantitative immunofluorescence was used to measure ALDH1 in 134 patients with NSCLC from Yale University and 296 patients with NSCLC from Sotiria and Patras University hospitals in Greece, using tissue microarrays. Patients were classified as positive or negative for ALDH1 based on the detection threshold for quantitative immunofluorescence. Patients with squamous cell carcinoma had higher scores than patients with adenocarcinoma. Detectable ALDH1 predicted better prognosis in both cohorts (<em>P</em> = 0.0035 for the Yale cohort; <em>P</em> = 0.0238 for the Sotiria/Patras cohorts). The effect of ALDH1 expression was independent of clinicopathologic factors in the Yale cohort (risk ratio = 3.2, <em>P</em> = 0.0008), but did not reach significance in the Sotiria/Patras cohort (hazard ratio = 1.51, <em>P</em> = 0.08). Among patients with adenocarcinoma, the ALDH1-negative group had shorter survival compared with the ALDH1-positive group in the Yale cohort (<em>P</em> = 0.00001), but not in the Sotiria/Patras cohort (<em>P</em> = 0.45). Unlike breast cancer, in which ALDH1 expression predicts poor outcome, in NSCLC our exploratory and retrospective study indicates that ALDH1 expression is associated with favorable outcome.
<br/>来源：医学专业新闻
链接：http://www.journals.elsevierhealth.com/periodicals/ajpa/article/S0002-9440(12)00519-6/images
还没有人评论，赶快抢个沙发